Adamed Pharma has opened two state-of-the-art laboratories in its Production and Logistics Center in Pabianice, Poland. Spanning over 800 square meters, these facilities focus on developing inhalation drugs and microbiological research. This marks the company’s entry into the field of inhalation therapies. The project aligns with a larger plan to invest nearly PLN 500 million by 2030 in pulmonary medicine, including innovative products for chronic respiratory diseases like asthma and COPD.
Focus on Pulmonary Solutions
One laboratory, costing approximately PLN 60 million, is dedicated to creating single-dose (DPI) and multi-dose (MDPI) inhalation products. These therapies are designed to address significant clinical and market needs in respiratory care. Adamed’s approach emphasizes strict adherence to regulatory standards and safety, especially when working with toxic substances. Advanced research is supported by cutting-edge equipment to ensure the highest quality formulations and devices.
The microbiological laboratory, valued at PLN 20 million, focuses on testing and validating drug purity. It also ensures compliance with production standards, bolstering the company’s capacity to support drug registration processes. This investment quadruples Adamed’s previous microbiological research capabilities.